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Abstract
Focal adhesion kinase (FAK) is strongly activated by integrins and growth factors and is essential 
for embryonic development. We previously showed that the C terminus of FAK is expressed as a 
separate protein termed FAK-related nonkinase (FRNK) in a smooth muscle cell–selective fashion 
and that FRNK functions to buffer FAK-dependent signals. We now show that FRNK is also 
transiently expressed in the neonatal myocardium, with peak levels occurring 5 to 7 days 
postnatal, just before cell cycle withdrawal. Using novel mouse models, we demonstrate that 
cardiac-selective expression of FRNK (leading to inhibition of FAK) starting at embryonic day 
10.5 leads to a severe ventricular noncompaction defect associated with reduced cardiomyocyte 
proliferation. Remarkably, postnatal expression of nearly identical levels of FRNK is well 
tolerated and does not affect viability or anabolic cardiac growth. Nonetheless, FRNK expression 
in the adult heart does attenuate pathological cardiac hypertrophy following aortic banding, 
confirming and extending our previous data that this compensatory response is blunted in FAK 
null hearts. Our mechanistic studies in cultured neonatal cardiomyocytes reveal that FRNK 
expression induces p38/p27kip-dependent cell cycle withdrawal and attenuates extracellular signal-
regulated kinase–dependent hypertrophic growth. These findings indicate that dynamic expression 
of FRNK in the neonatal heart may function to promote cardiomyocyte quiescence in an 
environment that is particularly rich in growth factors and growth promoting extracellular 
matrices.
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Robust, locally restricted myocyte proliferation is necessary for several stages of cardiac 
morphogenesis, and, although it has long been known that cardiomyocytes undergo terminal 
differentiation and exit from the cell cycle shortly after birth, the mechanisms that regulate 
fetal myocyte cell cycle progression and those that promote cell cycle withdrawal are not 
well understood.
The nonreceptor tyrosine kinase focal adhesion kinase (FAK) is strongly activated by both 
integrins and growth factors and is a likely candidate to integrate signals from these diverse 
pathways during growth and development.1 Germline deletion of FAK results in general 
mesodermal defects and embryonic lethality between embryonic day (E)8.5 to E10, and 
examination of the malformed hearts from these embryos indicated a putative function for 
FAK in cardiomyocyte maturation.2 However, because FAK can serve both structural and 
signaling roles within focal adhesions, it has been difficult to determine whether FAK 
activity per se is essential for regulating cardiomyocyte growth. Interestingly, our laboratory 
recently showed that FAK activity can be regulated by the endogenous expression of a 
separate protein comprising the carboxyl terminus of FAK, termed FRNK (FAK-related 
nonkinase) that acts as a dominant interfering mutant for FAK.3 FRNK transcription results 
from the utilization of an alternative start site within the FAK gene, and FRNK expression is 
independently regulated by a distinct promoter embedded within FAK intronic sequences.4,5 
Whereas FAK expression is ubiquitous relatively constantly during development, we 
previously found that FRNK protein was particularly high in the vasculature when smooth 
muscle cells (SMCs) are transitioning from a synthetic to contractile phenotype.4
We now present evidence that FRNK is also transiently expressed in the neonatal 
myocardium before cell cycle withdrawal. By conditionally expressing FRNK in the fetal 
and neonatal myocardium in the mouse, we show that FAK activity mediates both 
hyperplastic and pathological hypertrophic growth but not anabolic growth of the heart. Our 
findings lead us to propose that dynamic expression of FRNK in the neonatal heart may 
function to dampen cardiomyocyte cell cycle progression (and to facilitate cell cycle 
withdrawal) in an environment that is particularly rich in growth factors and growth-
promoting extracellular matrix (ECM).
Materials and Methods
Transgenic mice were generated and backcrossed to the C57black6 background. Mice were 
housed in the University of North Carolina Animal Care Facility, which is accredited by the 
Association for Assessment and Accreditation of Laboratory Animal Care International, and 
all experimental procedures were approved by the University of North Carolina Animal 
Care and Use Committee. See the expanded Materials and Methods section in the online 
data supplement at http://circres.ahajournals.org for a complete description of the reagents, 
DNA constructs, transgenic mouse generation, and general methods used for these studies.
Statistical Analysis
All quantitative data represent at least 3 separate experiments and are presented as means
±SEM. Means were compared by 2-tailed Student's t test. P<0.05 was considered 
DiMichele et al. Page 2













statistically significant, as indicated by an asterisk. All other data including, Western 
analysis, are representative of at least 3 individual experiments.
Results
Transient Expression of Cardiac FRNK
We previously reported that FRNK is dynamically and selectively expressed in SMCs 
during neonatal development and following vascular injury in adult rodents.4 However, 
during the course of our previous examination of FAK signaling in the developing 
myocardium,6 we made the somewhat surprising observation that FRNK is also transiently 
expressed in the neonatal myocardium. As shown in Figure 1a, peak FRNK protein levels 
were observed between postnatal day (P)5 and P7, whereas high levels of FAK were 
observed in the myocardium from E10.5 to P7. During heart development, 2 forms of FRNK 
(with apparent molecular masses of 41 and 43 kDa) appear to be present, consistent with our 
previous findings in SMCs.4 (See the online data supplement for further discussion.) We 
next isolated cardiomyocytes from neonatal rat hearts and performed Western analysis to 
ensure that FRNK was selectively expressed in these cells. As shown in Figure 1b, 
expression of FRNK in purified cardiomyocytes mirrored the levels found in the intact 
myocardium, with high levels observed in isolated P7 relative to P0 cardiomyocytes. The 
temporal expression of FRNK in neonatal cardiomyocytes highlights the possibility that 
precise control of FAK signaling might be necessary for proper growth of the heart.
FRNK transcription results from the utilization of an alternative promoter embedded 
between exons encoding the FAK-kinase domain and the FAK carboxyl-terminal protein-
binding region,5 and we showed that FRNK-specific mRNAs are initiated within a unique 5′ 
noncoding exon in vascular SMCs and smooth muscle–containing tissues.4 However, data 
also indicate that FRNK-like peptides can be generated in cells by protease degradation of 
FAK.7,8 To discriminate between these 2 possibilities, we subjected ventricular myocardial 
RNAs (isolated from the apex of the heart) to quantitative RT-PCR using probes and 
primers directed against the FRNK noncoding exon. As shown in Figure 1c, FRNK mRNA 
was apparent in ventricular myocardial tissue, and the levels peaked between P1 and P4, 
correlating well with FRNK protein patterns detected by immunoblot analysis. This transient 
expression of FRNK in the early postnatal heart coincides with the window in which 
cardiomyocytes transition to terminally differentiated cells. Because our previous data 
indicated that FRNK functions to buffer of FAK-dependent growth signals in SMCs,9 we 
reasoned that FRNK might function to decrease DNA synthesis and possibly promote cell 
cycle withdrawal in cardiomyocytes.
Generation of FRNKloxP Mice
To carefully examine the function of FRNK in the myocardium in vivo, we generated a Cre-
dependent transgenic mouse model in which FRNK can be overexpressed in a time-and 
tissue-restricted fashion (Figure 2A; see the expanded Results section in the online data 
supplement for description). Western blot analysis revealed moderate levels of green 
fluorescent protein (GFP) expression in all tissues examined from 2 independent transgenic 
lines of these so-named FRNKloxp mice, whereas myc-FRNK was undetectable in these 
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lysates (Figure I in the online data supplement). Immunohistochemistry for GFP revealed 
uniform expression throughout the heart (Figure 2d) and several other tissues as expected 
(data not shown).
Targeted Expression of FRNK in the Myocardium
By crossing the FRNKloxP mice to well-established Nkx2.5Cre and MLC2vCre lines, we 
were able to explore the functional consequences of FRNK expression early and late during 
cardiac development.10,11 FRNKloxP/MLC2vCre double transgenic mice (hereafter referred 
to as FRNKMlc2v) were born in the expected Mendelian ratios, and Western blot analysis 
revealed cardiac-restricted expression of myc-FRNK from P1 onwards (Figure 2b and 2c 
and Online Figure II). Moreover, only a few GFP-positive cells were detected by 
immunohistochemistry in the ventricles of the FRNKMlc2v hearts, indicating nearly 
complete transgene recombination (Figure 2d). Importantly, hearts from FRNKMlc2v mice 
exhibited decreased FAK activity relative to hearts from control FRNKloxP mice, as 
determined by Western blotting with an anti–pFAK Y-397 antibody (Figure 2e). 
Nonetheless, FRNKMlc2v mice did not exhibit any overt abnormalities and had normal life 
expectancies (Figure 2f and Online Table I).
In stark contrast, crossing FRNKloxP mice with the Nkx2.5Cre line yielded no viable double 
transgenics, and subsequent studies revealed that embryonic lethality in FRNKNkx2.5 mice 
occurred between E14.5 and E16.5 (Figure 2f and Online Table I). Western analysis 
revealed detectable levels of myc-FRNK as early as E10.5 in FRNKNkx2.5 hearts (data not 
shown), with maximal levels observed by E13.5 (Figure 2g). Importantly, although the 
timing of myc-FRNK expression was different between the 2 models, the maximal levels of 
myc-FRNK protein expressed in the hearts of FRNKNkx2.5 and the FRNKMlc2v mice were 
remarkably similar and modestly (3-fold) higher than levels of endogenous FRNK expressed 
in control hearts at P7 (see Online Figure II for quantification). Collectively, these data 
indicate that embryonic cardiac development is exquisitely sensitive to FRNK expression 
(and a reduction in FAK activity), whereas further postnatal development is FAK-
independent.
Histological and Morphological Analysis of FRNKNkx2.5 Mice
Gross morphology of FRNKNkx2.5 embryos at E14.5 revealed extreme hydrops fetalis and 
blood pooling, likely attributable to cardiac failure in these embryos (Figure 3a). 
Histological examination of coronal sections through the FRNKNkx2.5 hearts revealed 
similar heart size and ventricular wall thickness at E10.5 (the onset of myc-FRNK 
expression). However, as development progressed from E10.5 to E14.5, little growth was 
observed in the FRNKNkx2.5 hearts in comparison to genetic controls, which underwent 
dramatic expansion of the ventricular walls and growth of the interventricular septum 
(Figure 3b). Whereas trabeculae were reasonably well formed in the FRNKNkx2.5 hearts, 
compaction of the ventricular chambers was significantly impaired. Indeed, quantification of 
E14.5 coronal heart sections revealed a 48% reduction in cell density in the FRNKNkx2.5 
hearts compared to age-matched controls (Figure 3c). There were no overall gross or 
histological differences observed in other tissues derived from nkx2.5-expressing cells 
compared to genetic controls at E14 (Online Figure IV and Online Results), indicating that 
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lethality in FRNKNkx2.5 embryos was likely attributable to heart failure at approximately 
E15.5.
myc-FRNK Expression Attenuates Myocyte Proliferation
Because no significant differences were observed in the cardiac differentiation program or 
the extent of apoptosis between E13.5 FRNKNkx2.5 and genetic control hearts (Figure 3d 
and Online Results), we next sought to determine whether FRNK expression led to a 
proliferation defect. Indeed the number of 5-bromodeoxyuridine (BrdUrd)-labeled cells in 
the ventricles of E13.5 FRNKNkx2.5 hearts was significantly reduced when compared to 
genetic control hearts (especially within the compact zone; Figure 4). We did not observe 
significant differences in BrdUrd incorporation in any other tissues examined (data not 
shown). We next turned to cultured primary cardiomyocytes to determine whether FRNK 
expression could directly impair proliferation of neonatal cardiomyocytes. To this end, we 
infected P0 cardiomyocytes with GFP or GFP-FRNK adenovirus and examined the rate of 
proliferation of these cells in serum-containing media. Under these conditions the rate of 
BrdUrd incorporation in GFP-infected cells was ≈ 18%, whereas only 4% of the FRNK-
infected cells were BrdUrd-positive (Figure 5a and 5f). In addition to this striking reduction 
in BrdUrd incorporation, the FRNK-infected cells exhibit a blunted hypertrophic response to 
serum, as assessed by reduced cell size and sarcomeric actin organization (as assessed by 
cardiac troponin T staining; see Online Figure VIII, a, for higher-power images), consistent 
with our previous findings.12 Collectively, these data indicate that FRNK expression 
negatively regulates embryonic and neonatal cardiomyocyte growth but does not affect cell 
survival during postnatal heart development.
myc-FRNK Expression Regulates Mitogen-Activated Protein Kinase Signaling
Previous studies have revealed that the mitogen-activated protein kinases (MAPKs) 
extracellular signal-regulated kinase (ERK) and p38 play positive and negative roles, 
respectively, in regulating cardiomyocyte cell cycle progression.13–17 Interestingly, we 
found that ERK activity (Figure 5b) and expression of the ERK-dependent immediate early 
gene c-fos (Online Figure V, b) were each significantly reduced in E13.5 FRNKNkx2.5 hearts 
compared to littermate controls at this time point (the peak of myocyte proliferation). In 
contrast, p38 activity was significantly elevated in FRNKNkx2.5 hearts (Figure 5b). To 
confirm that regulation of these MAPKs was attributable to a primary change in FRNK 
expression, we examined activation of these pathways in cultured cardiomyocytes. Indeed, 
ectopic expression of FRNK significantly enhanced p38 activity in a time-dependent fashion 
but attenuated growth factor (fibroblast growth factor [FGF]-2 and insulin-like growth factor 
[IGF]-1)–induced ERK activity in these cells (Figures 5c and 6b; see Online Figure VI for 
quantification).
To determine the functional importance of these pathways with respect to FRNK-dependent 
inhibition of myocyte proliferation, we explored whether inhibition of p38 or activation of 
ERK would restore myocyte proliferation in FRNK-expressing cardiomyocytes. As shown 
in Figure 5a and 5f, treatment with the p38 inhibitor SB203580 (10 μmol/L) enhanced 
BrdUrd incorporation in GFP-expressing cells (by 2-fold) and even more markedly 
enhanced BrdUrd incorporation in FRNK-expressing cells by 5-fold (to 25%; surpassing the 
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level observed in GFP control cells). With respect to ERK activation, we found that 
treatment of GFP-expressing cardiomyocytes with the MEK1 inhibitor UO927 reduced 
BrdUrd incorporation by ≈50%, indicating that ERK activation is necessary for maximal 
serum-stimulated BrdUrd incorporation. However, adenoviral-mediated expression of 
constitutively active MEK1, which led to sustained elevated ERK activity (see Online 
Figure VIII, b), induced only a modest increase in BrdUrd incorporation in both GFP- and 
FRNK-infected cells, and no synergy was found on treatment with constitutively active 
MEK and the p38 inhibitor (Figure 5f; see Online Figure VIII, a, for representative images). 
Importantly, FRNK was expressed in comparable levels under all treatment groups, as 
assessed by Western analysis (Online Figure VIII, b).
We next evaluated the expression levels of the cell cycle inhibitor p27kip (a key p38-
dependent cell cycle regulator) in GFP- and FRNK-expressing cardiomyocytes. As shown in 
Figure 5e, expression of p27kip was markedly upregulated in FRNK-expressing cells in 
comparison to the GFP-expressing controls. Notably, treatment of the FRNK-expressing 
cells with SB203580 restored expression of p27 kip to control levels. p27kip levels were also 
significantly elevated in E13.5 FRNKNkx2.5 hearts in comparison to genetic controls (Figure 
5b). Collectively, these data indicate that FRNK expression attenuates cardiomyocyte cell 
cycle progression and induces cell cycle withdrawal, in large part, by a mechanism that 
involves enhanced activation of p38, an important negative regulator of cardiomyocyte 
cytokinesis.16,17 Interestingly, we also observed upregulation of p38 activity in FAK-null 
hearts (see Online Results and Online Figure VII), indicating that FRNK expression likely 
dampens cardiomyocyte proliferation by relieving FAK-dependent repression of p38.
FRNKMlc2v Mice Exhibit Normal Anabolic Growth but a Diminished Response to Pressure 
Overload
Because FAK activity was clearly necessary for growth of the fetal heart, we carefully 
assessed the affect of FRNK expression on postnatal myocardial growth. After extensive 
measurements of heart size, heart weight, cardiomyocyte cross-sectional area, myofibrillar 
organization, collagen deposition, and physiological function (by echocardiography), we 
concluded that there were no significant differences in hearts from FRNKLoxP and 
FRNKMlc2v mice up to 8 months of age (Figure 6a and Online Table II). These data reveal 
that FRNK expression is well tolerated in terminally differentiated myocytes and imply that 
FAK activity is not necessary for anabolic growth of the heart.
Postnatal anabolic (physiological) hypertrophic growth is known to be controlled primarily 
by IGF-1– and growth hormone–dependent stimulation of the phosphatidylinositol 3-
kinase/AKT/p70S6K protein synthesis pathway.18–23 Interestingly, we found that whereas 
IGF-1–stimulated (and FGF-stimulated) ERK activation was attenuated by FRNK 
expression in neonatal cardiomyocytes, IGF-1–stimulated activation of AKT was not 
(Figure 6b). Moreover, IGF-1 stimulation led to a comparable induction of AKT in 
cardiomyocytes plated on either fibronectin (which promotes β1 integrin–dependent FAK 
activation) or on type I collagen (which does not promote FAK activation; Figure 6c), 
whereas IGF-stimulated (and FGF-stimulated) ERK activity required fibronectin (Figure 
6d). Collectively, these data reveal that FRNK/FAK signaling modulates a subset of 
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myocyte growth responses, effecting signals that regulate cell cycle progression but not 
anabolic growth.
Although FAK protein levels and basal activity are relatively low in the adult myocardium, 
several reports have indicated that FAK activity is markedly induced following mechanical 
overload, and we recently published a report showing that myocyte-restricted FAK deletion 
attenuates compensatory hypertrophic remodeling following pressure overload.24 However, 
questions remain as to whether FAK plays a structural role or signaling role in this setting. 
Thus, we next strove to determine whether specific inhibition of FAK activity in vivo in the 
FRNKMlc2v line was sufficient to blunt pressure overload–induced hypertrophic remodeling. 
To this end, we subjected FRNKMlc2v and wild-type littermate control mice to a minimally 
invasive aortic banding procedure that provides an approximate 50% reduction in the lumen 
of the ascending aorta.25 Following chronic aortic constriction, we examined the mice for a 
variety of hypertrophic changes. As shown in Figure 7a, FRNKMlc2v mice had significantly 
lower heart weight versus body weight in comparison to genetic controls following banding. 
In addition, myocyte cross-sectional area was significantly lower in postbanded FRNKMlc2v 
hearts compared to postbanded genetic controls (Figure 7b). Echocardiographic analysis of 
genetic control mice also revealed significant differences in the extent of remodeling 
following banding. Notably, the pressure overload–induced increase in thickness of the left 
ventricular wall and intraventricular septum were both significantly reduced in the 
FRNKMlc2v hearts when compared to the genetic controls (Figure 7c). Hearts from 
FRNKMlc2v and control mice were also analyzed for hypertrophic marker gene expression 
by quantitative RT-PCR before and after banding. Importantly, the fold increase in the 
canonical hypertrophic marker gene, atrial natriuretic factor was significantly attenuated in 
the FRNKMlc2v hearts in comparison to the genetic controls (control, 66±10.5-fold increase 
in banded over sham; FRNK, 3.8±1.2-fold increase in banded over sham; P<0.05; n=6 per 
genotype).
As expected, adrenergic agonist-induced ERK activation was also dampened in FRNKMlc2v 
hearts in comparison to those from genetic controls (Figure 7d). Interestingly, we noted in 
our proliferation studies that ectopic expression of Mek1 (but not inhibition of p38) reversed 
the hypertrophic growth defect in FRNK-expressing cells (see Figure 5a and Online Figure 
VIII, a). Subsequent studies revealed that expression of constitutively active Mek1 induced a 
2-fold increase in cell area in FRNK-expressing cardiomyocytes and enhanced sarcomeric 
actin organization in these cells (a hallmark of pathological hypertrophic growth; Online 
Figure VIII, c and d). Collectively, these data indicate that promotion of p38 activity and 
attenuation of ERK activity are likely the major mechanisms by which FRNK expression 
represses proliferation and pathological hypertrophic growth, respectively.
Discussion
It is clear that coordinated signaling through integrins and growth factors plays an important 
role in regulating both cardiac morphogenesis and the progression of cardiac disease, but 
how these processes are fine-tuned during the different phases of heart growth and 
development is unknown. Herein, we show that FRNK, the endogenous inhibitor of FAK, is 
transiently expressed in heart, with peak levels occurring at P5 to P7, when cardiomyocytes 
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are transitioning to terminally differentiated cells. Using novel mouse models, we 
demonstrated that cardiac-selective expression of FRNK (leading to inhibition of FAK) 
starting at E10.5 led to a severe ventricular noncompaction defect associated with impaired 
cardiomyocyte proliferation. Remarkably, postnatal expression of nearly identical levels of 
FRNK was well tolerated and did not affect viability or anabolic cardiac growth but did 
attenuate pressure overload–induced hypertrophic remodeling. Collectively, our mechanistic 
studies indicate that FAK regulates p38-dependent myocyte proliferation in the developing 
myocardium and ERK-dependent promotion of pathological hypertrophy following 
biomechanical stress but that FAK activity is dispensable for AKT-dependent physiological, 
anabolic growth of the heart.
Our recent demonstration that FAK activity is enhanced in tissues and cells derived from 
FRNK−/− mice strongly supports the hypothesis that the dynamic regulation of FRNK 
expression can impart specific spatial and temporal control of FAK activity in vivo.26 
Additionally, a very recent publication revealed that myocyte-specific deletion of FAK in 
mid-gestation (using the Mlc2aCre line) phenocopies the defects we observed in the 
FRNKNkx2.5 embryos including embryonic lethality, global edema, thin ventricle wall, and 
reduced rates of myocyte proliferation, although the underlying signaling mechanisms were 
not explored.27 Thus, mice with cardiac-restricted expression of FRNK exhibit remarkably 
similar developmental and hypertrophic growth defects as mice with similar temporal 
deletion of FAK. Collectively, these studies strongly support the notion that the effects of 
FRNK are mediated by inhibition of FAK-dependent signals and that FAK activity is 
necessary to promote myocyte proliferation in a cell-autonomous fashion.
Proliferation of cardiomyocytes within the compact zone at mid-gestation is necessary to 
support the increasing hemodynamic load of the embryo, and a large body of evidence 
indicates that FGF-, IGF-, and transforming growth factor/bone morphogenetic protein–
induced signals appear to play a critical role in this process because genetic deletion of these 
ligands or their receptors lead to compaction defects.15 In terms of signaling, many of these 
receptors are linked to the MAPK signaling pathways terminating in activation of ERK, c-
Jun N-terminal kinase, and p38. Several recent studies indicate that p38 may function at a 
G2/M checkpoint to block cardiomyocyte cell cycle progression,16,17 including the findings 
that (1) p38α activity is inversely correlated with cardiac growth during development; (2) 
activation of p38 in vivo (by forced expression of MKK3) reduced fetal cardiomyocyte 
proliferation; and (3) cardiac-restricted deletion of p38α significantly enhanced myocyte 
proliferation. Our studies reveal that expression of FRNK limits cardiomyocyte proliferation 
and induces cell cycle arrest in a p38-dependent fashion. Indeed, we found that expression 
of FRNK (or inactivation of FAK) promotes p38 activity and regulates expression of the 
p38-dependent cell cycle modifier, p27kip and that pharmacological inhibition of p38 
restores DNA synthesis in FRNK-expressing cells. Thus, it is tempting to speculate that 
basal FAK activity may act to repress p38, a necessary function for tyrosine kinase–
dependent growth, in addition to growth induced by equally important parallel pathways 
such as the bone morpho-genetic protein/Smad4 signaling cascade.28,29
Our studies reveal that the timing of FRNK expression in the postnatal heart corresponds to 
the window during which cardiomyocytes exit the cell cycle. (See the online data 
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supplement for further discussion of FRNK expression in the myocardium.) Because 
misexpression of FRNK can attenuate proliferation of embryonic cardiomyocytes, we 
speculate that transient expression of endogenous FRNK in the perinatal heart is necessary 
to achieve quiescence in this growth-promoting environment. Several studies indicate that 
the cardiomyocyte growth state in the developing heart correlates with regulated shifts in 
expression of ECM and integrin receptors and the ability of these matrices to support 
myocyte growth in vitro.30,31 Thus, we speculate that FRNK may not be necessary in the 
adult myocardium, because although growth factors such as FGF-2 and IGF-1 continue to be 
highly expressed, the ECM composition in the adult heart (mainly type I collagen) is not 
growth-permissive. Interestingly, periostin (a component of the ECM that activates β1, 3, 
and 5 integrins) is also highly expressed in the developing myocardium and is re-expressed 
in the diseased adult heart and a recent high profile study demonstrated that recombinant 
periostin was sufficient to induce cell-cycle re-entry in adult cardiomyocytes both in vitro 
and in vivo.32 These data underscore the importance of integrin signaling in the regulation 
of cardiomyocyte cell cycle and support the notion that FAK activity may play a critical role 
in this response.
Our new studies also reveal that FAK does not merely have a cyto-architectural role in the 
adult myocardium, but has a key enzymatic function to transmit pressure-induced 
compensatory progrowth signals. Interestingly, most known genetic mutations leading to 
familial hypertrophic cardiomyopathy (HCM, which resembles concentric compensatory 
hypertrophy) are attributable to point mutations in sarcomeric proteins,33 and because these 
structural molecules are involved in the generation of force that is ultimately transmitted to 
the cell membrane and ECM, it will be interesting to determine whether FAK can also act to 
sense the altered load imparted by these mutant muscle fibers. We speculate that FAK might 
be aberrantly activated in the hearts of mice carrying hypertrophic cardiomyopathy 
mutations and that FRNK expression might attenuate the extent of hypertrophic remodeling 
observed. (See the online data supplement for further discussion regarding the necessity of 
FAK activity for pathological but not anabolic growth of the heart.)
In summary, we show that FRNK expression increases in the myocardium at birth and that 
FRNK has the capacity to dampen cardiomyocyte proliferation by enhancing activity of the 
cell cycle inhibitor p38. FRNK−/− mice were recently generated, and these mice were 
reportedly born in the expected Mendelian frequency and showed no gross phenotype.34 
However, our studies indicate that a specific evaluation of cardiac growth in these mice is 
warranted. Additionally, because we provide evidence that FAK provides cues to neutralize 
signals responsible for cell cycle restriction, it will also be of interest to determine to 
whether targeted FAK activation can induce post-mitotic cardiomyocyte cell cycle reentry.
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Endogenous cardiac FRNK expression during heart development. a and b, Western blots of 
cardiac lysate from indicated embryonic (E), postnatal day (p), or adult C57black6 mice (a) 
or cardiomyocytes isolated from P0 or P7 neonatal rat hearts (b). Western blots are 
representative of at least 3 separate experiments. c, Quantitative RT-PCR for FRNK 
message in C57black6 hearts. FRNK levels were normalized to 18S and presented as fold 
change over message levels detected at E13.5±SEM (n=at least 4 for each time point).
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Generation of transgenic mice with temporal and myocardial-restricted FRNK expression. a, 
Schematic of construct used to generate FRNKLoxP transgenic mice. b and c, Western blot 
analysis of myc-FRNK expression in tissues from FRNKMlc2v double transgenic mice. d, 
Immunohistochemical analysis of GFP expression levels in left ventricle from 8-week-old 
FRNKLoxP or FRNKMlc2v mice. e, Western analysis for active, phospho-Y397 FAK, or total 
FAK in ventricular lysate from 1-week FRNKLoxP or FRNKMlc2v mice. f, Viable 
FRNKNkx2.5 or FRNKMlc2v offspring at indicated time points. Dashed line denotes expected 
Mendelian ratio of 25%. See Online Table I for number of animals per time point. g, 
Western blot analysis of myc-FRNK expression in hearts of FRNKMlc2v and FRNKNkx2.5 
double transgenic mice at the indicated ages. Western blots are representative of at least 3 
separate experiments.
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Histological and morphological analysis of FRNKNkx2.5 mice. a, Gross morphology of 
genetic control and FRNKNkx2.5 embryos at E14.5. b, Hematoxylin/eosin-stained sections of 
hearts from the indicated embryonic day. c, Cellular density was quantified in serial sections 
from E14.5 genetic control and FRNKNkx2.5 hearts. d, Ventricle sections from E13.5 genetic 
control and FRNKNkx2.5 mice were costained with FragEL and cardiac troponin T to 
identify apoptotic cardiomyocytes. Graphical data are expressed as means±SEM (n=6 for 
each condition; *P<0.01).
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FRNKNkx2.5 hearts exhibit a noncompaction defect associated with reduced myocyte 
proliferation. a, High power hematoxylin/eosin-stained images of left ventricular compact 
zone from E14.5 FRNKloxP and FRNKNkx2.5 embryos. b, BrdUrd incorporation in E13.5 
FRNKloxP and FRNKNkx2.5 ventricles. c, Quantification of BrdUrd-positive nuclei in heart 
(means±SEM; n≥6; *P<0.01).
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FRNK expression attenuates DNA synthesis and promotes cell cycle withdrawal in a p38-
dependent fashion. a, BrdUrd incorporation in isolated cardiomyocytes (P0) infected with 
GFP- or GFP-FRNK adenovirus (10 multiplicities of infection). Cells were maintained in 
serum-containing medium and treated with vehicle or SB203580 (10 μmol/L) as indicated. 
Costaining with anti–cardiac troponin T (cTnT) was performed to identify cardiomyocytes. 
b, Western blot analysis in cardiac lysates from E13.5 FRNKloxP and FRNKNkx2.5 embryos. 
c and d, Rat neonatal cardiomyocytes (P0) plated on fibronectin were infected with GFP- or 
GFP-FRNK adenovirus (10 multiplicities of infection), replaced with serum-free media, and 
treated with FGF-2 (c) or maintained in serum-containing conditions (d) for the indicated 
times before immunoblotting. See Online Figure VI (a through c) for densitometric 
quantification of 3 separate experiments. e, Isolated cardiomyocytes, treated as described for 
a, were processed by immunocytochemistry for p27kip (myocytes are identified by striated 
actin visualized by phalloidin). f and g, Quantification of BrdUrd- and p27kip-positive 
cardiomyocytes (means±SEM; n=3; minimum of 300 cells/condition). Additional 
representative images are provided in Online Figure VIII.
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Anabolic cardiac growth and AKT signaling are not affected by FRNK expression. a, Low- 
and high-power images of cross-sections of 8-week-old FRNKloxp and FRNKMlc2v hearts 
stained with trichrome (blue corresponds to collagen) (top and middle) or with an anti–
cardiac troponin T antibody (bottom). b and c, Rat neonatal cardiomyocytes were infected as 
described above or plated on fibronectin (FN) or collagen (COL) (10 μg/mL) and treated 
with IGF-1 or FGF-2 for the indicated times. Lysates were immunoblotted for phospho- and 
total ERK and AKT. Western data are representative of at least 3 separate experiments. See 
Online Figure VI for quantification.
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FRNKMlc2v mice exhibit attenuated pressure overload–induced hypertrophy. a, Left 
ventricular (LVW) and body (BW) weight measurements were taken from control and 
FRNKMlc2v animals at baseline and following 14 days of transaortic constriction (TAC). 
Data are presented as the means±SEM (n=4/time point per genotype; *P<0.05). b, Cross-
sectional myocyte area in sham and banded control and FRNKMlc2v hearts (n=at least 130 
cells from 4 mice/condition; *P<0.05 compared to control banded). c, M-mode 
echocardiographic measurements of the left ventricle from baseline and 14-day banded 
control and FRNKMlc2v mice during diastole (d) and systole (s). Data are expressed as 
percentage of change from pre- to post-TAC. #P<0.05 when compared with percentage of 
change in control mice. d, Control (C) and FRNKMlc2v (F) mice were injected IP with 
vehicle or adrenergic cocktail for 7 minutes containing phenylephrine and isoproterenol (30 
mg/kg each), and ventricular lysate was processed for Western blot analysis.
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